These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion. Song S; Wang C; Wang S; Siegel RA; Sun CC Int J Pharm; 2021 Dec; 610():121216. PubMed ID: 34688849 [TBL] [Abstract][Full Text] [Related]
5. A novel architecture for achieving high drug loading in amorphous spray dried dispersion tablets. Mudie DM; Buchanan S; Stewart AM; Smith A; Shepard KB; Biswas N; Marshall D; Ekdahl A; Pluntze A; Craig CD; Morgen MM; Baumann JM; Vodak DT Int J Pharm X; 2020 Dec; 2():100042. PubMed ID: 32154509 [TBL] [Abstract][Full Text] [Related]
6. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices. Pepin XJH; Moir AJ; Mann JC; Sanderson NJ; Barker R; Meehan E; Plumb AP; Bailey GR; Murphy DS; Krejsa CM; Andrew MA; Ingallinera TG; Slatter JG Eur J Pharm Biopharm; 2019 Sep; 142():435-448. PubMed ID: 31306750 [TBL] [Abstract][Full Text] [Related]
7. Development of an Amorphous Solid Dispersion Formulation for Mitigating Mechanical Instability of Crystalline Form and Improving Bioavailability for Early Phase Clinical Studies. Chiang CW; Lubach JW; Chen T; Chin S; Ly J; Zhang W; Hou HH; Nagapudi K Mol Pharm; 2023 May; 20(5):2452-2464. PubMed ID: 37010134 [TBL] [Abstract][Full Text] [Related]
8. Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution. Jara MO; Warnken ZN; Sahakijpijarn S; Thakkar R; Kulkarni VR; Christensen DJ; Koleng JJ; Williams RO Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559062 [TBL] [Abstract][Full Text] [Related]
9. Impact of Gastric pH Variations on the Release of Amorphous Solid Dispersion Formulations Containing a Weakly Basic Drug and Enteric Polymers. Nguyen HT; Van Duong T; Taylor LS Mol Pharm; 2023 Mar; 20(3):1681-1695. PubMed ID: 36730186 [TBL] [Abstract][Full Text] [Related]
10. Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor. Cui Y; Chiang PC; Choo EF; Boggs J; Rudolph J; Grina J; Wenglowsky S; Ran Y Int J Pharm; 2013 Sep; 454(1):241-8. PubMed ID: 23834830 [TBL] [Abstract][Full Text] [Related]
11. Utility of Films to Anticipate Effect of Drug Load and Polymer on Dissolution Performance from Tablets of Amorphous Itraconazole Spray-Dried Dispersions. Honick M; Sarpal K; Alayoubi A; Zidan A; Hoag SW; Hollenbeck RG; Munson EJ; Polli JE AAPS PharmSciTech; 2019 Nov; 20(8):331. PubMed ID: 31677012 [TBL] [Abstract][Full Text] [Related]
12. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. Kennedy M; Hu J; Gao P; Li L; Ali-Reynolds A; Chal B; Gupta V; Ma C; Mahajan N; Akrami A; Surapaneni S Mol Pharm; 2008; 5(6):981-93. PubMed ID: 19434920 [TBL] [Abstract][Full Text] [Related]
13. Impact of Drug-Rich Colloids of Itraconazole and HPMCAS on Membrane Flux in Vitro and Oral Bioavailability in Rats. Stewart AM; Grass ME; Brodeur TJ; Goodwin AK; Morgen MM; Friesen DT; Vodak DT Mol Pharm; 2017 Jul; 14(7):2437-2449. PubMed ID: 28591516 [TBL] [Abstract][Full Text] [Related]
14. Effects of Surfactants on Itraconazole-Hydroxypropyl Methylcellulose Acetate Succinate Solid Dispersion Prepared by Hot Melt Extrusion III: Tableting of Extrudates and Drug Release From Tablets. Solanki NG; Kathawala M; Serajuddin ATM J Pharm Sci; 2019 Dec; 108(12):3859-3869. PubMed ID: 31542437 [TBL] [Abstract][Full Text] [Related]
15. Downstream processing of spray-dried ASD with hypromellose acetate succinate - Roller compaction and subsequent compression into high ASD load tablets. Sauer A; Warashina S; Mishra SM; Lesser I; Kirchhöfer K Int J Pharm X; 2021 Dec; 3():100099. PubMed ID: 34765966 [TBL] [Abstract][Full Text] [Related]
16. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538 [TBL] [Abstract][Full Text] [Related]
17. Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin. Salmani JM; Lv H; Asghar S; Zhou J Pharm Dev Technol; 2015 Jun; 20(4):465-72. PubMed ID: 24490758 [TBL] [Abstract][Full Text] [Related]
18. Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform. Lennernäs H; Brisander M; Liljebris C; Jesson G; Andersson P Clin Pharmacol Drug Dev; 2024 Sep; 13(9):985-999. PubMed ID: 38808617 [TBL] [Abstract][Full Text] [Related]
19. Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion. Van Nguyen H; Baek N; Lee BJ Int J Pharm; 2017 May; 523(1):189-202. PubMed ID: 28342789 [TBL] [Abstract][Full Text] [Related]
20. Characterizing and Exploring the Differences in Dissolution and Stability Between Crystalline Solid Dispersion and Amorphous Solid Dispersion. Wang X; Zhang L; Ma D; Tang X; Zhang Y; Yin T; Gou J; Wang Y; He H AAPS PharmSciTech; 2020 Sep; 21(7):262. PubMed ID: 32975680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]